BreastCT.com Debuts as Go-To Resource for Breast CT Technology & Izotropic’s IzoView Device
Rhea-AI Summary
Izotropic Corporation (OTCQB: IZOZF) has launched BreastCT.com, a comprehensive educational platform focused on breast CT technology and the company's IzoView Breast CT Imaging System. The website aims to educate about dedicated breast CT technology, particularly highlighting its potential in addressing breast cancer detection challenges for the 50% of women with dense breast tissue.
With IzoView's engineering phase now complete, the platform will evolve through clinical studies, regulatory phases, and commercial launch preparations. The site also contextualizes Izotropic's position by featuring successful public companies that have established new imaging categories, helping build market recognition ahead of future milestones.
Positive
- Engineering phase of IzoView Breast CT Imaging System is complete
- Platform targets large market opportunity with 50% of women having dense breast tissue
- Strategic positioning alongside successful imaging companies for market recognition
Negative
- Product still requires clinical studies and regulatory approvals before commercialization
News Market Reaction – IZOZF
On the day this news was published, IZOZF gained 1.25%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of BreastCT.com, a new online platform supporting the Company’s awareness initiatives.
BreastCT.com has been created as a central educational resource on dedicated breast CT technology and the Company’s IzoView Breast CT Imaging System, with a focus on its potential to address persistent challenges in detecting breast cancer in the
This new content positions Izotropic within a broader industry context by highlighting public companies that have successfully created and led new imaging categories. This approach gives audiences a clear frame of reference for where IzoView Breast CT could fit within an evolving market to build recognition ahead of future regulatory and commercial milestones.
At strategic times, Izotropic will integrate native advertising campaigns into BreastCT.com to help drive awareness in alignment with the Company’s goals.
About Izotropic:
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
What is the purpose of Izotropic's new BreastCT.com website?
What stage is Izotropic's (IZOZF) IzoView Breast CT System in development?
How many women could benefit from Izotropic's (IZOZF) breast CT technology?
What is Izotropic's (IZOZF) marketing strategy for BreastCT.com?
